secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001437749-25-001106
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M
------------------------------------------------------------------------------

- Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.
- FY2025 target total global revenue ~$540M, including BRIUMVI U.S. net product revenue ~$525M; target opex ~$300M.
- 2025 milestones: commence pivotal program for subcutaneous BRIUMVI; evaluate 30-min infusion; enroll in autoimmune trials.
- Year-end 2024 cash position approx. $310M.
- CEO states 2024 revenue far exceeded initial expectations; BRIUMVI well positioned for continued growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/0001437749-25-001106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774925001106/tgtx20250114_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer